Antimicrobial Susceptibility Report

January 1, 2024 to December 31, 2024

Central West Out Patient (Excluding Hospitals)

Urinary Tract Pathogens (in Order of Frequency) - % Susceptible

Organism	Number of Isolates	Amox clavulanic	Ampicillin	Cefazolin (1)	Ceftriaxone	Ciprofloxacin	Fosfomycin	Gentamicin	Meropenem	Nitrofurantoin	Trimethoprim-Sulfamethoxazole
E. coli ^	8646	72	51	76	81	56	99	91	100	97	71
Enterococcus species ^^^^	2214										
Klebsiella pneumoniae *	1382	89		90	91	85		97	100	44	90
Group B Streptococcus ^^	1183										
Proteus mirabilis +	400	96 n:399	82 n:399	90 n:399	96 n:399	87 n:399		93 n:399	99 n:399		83 n:399
Staphylococcus saprophyticus ^^^	255										

Organism Notes:

* Includes ESBL and AMP-C isolates (8.8% of total Klebsiella pneumoniae isolates identified as ESBL and AMP-C).

^ Includes ESBL and AMP-C isolates (18.6% of total E.coli isolates identified as ESBL and AMP-C).

^^ This isolate is predictably susceptible to Penicillin.

^^^ Acute and uncomplicated urinary tract infections due to Staphylococcus saprophyticus will respond to commonly used antibiotics including Nitrofurantoin, Trimethoprim-Sulfamethaxazole and Fluoroquinolones.

^^^^ Clindamycin, Trimethoprim/Sulfamethoxazole and all Cephalosporins are ineffective against Enterococcus species. Enterococcus isolates recovered from urine are generally susceptible to amoxicillin and nitrofurantoin. Susceptibility to Amoxicillin is 97.9% and to Nitrofurantoin is 96.5%

+ Includes ESBL and AMP-C isolates (3.3% of total Proteus mirabilis isolates identified as ESBL and AMP-C).

Antibiotic Notes:

(1) Cefazolin interpretation predicts results for Cephalexin (Keflex) in accordance with CLSI standards for urinary sites only (not systemic).

All Other Specimen Types excluding (Urines and Surveillance) - Organisms in Order of Frequency - % Susceptible

Organism	Number of Isolates	Cefazolin	Ceftazidime	Ciprofloxacin	Clindamycin	Cloxacillin	Erythromycin	Tetracycline (2)	Trimethoprim-Sulfamethoxazole
Group A Streptococcus ^^	2613								
Staphylococcus aureus ^^^	664	74 n:552			80 n:552	74 n:552	68 n:552	94 n:552	97 n:545
Pseudomonas aeruginosa	181		98	88					
Group B Streptococcus ^^	70								

Organism Notes:

^^ This isolate is predictably susceptible to Penicillin.

^^^ Includes Methicillin Resistant S.aureus (MRSA). MRSA is resistant to all B-Lactams (penicillins, cephalosporins, B-lactam/B-lactamase inhibitor combinations, and carbapenems). MRSA constitutes 23.8% of total Staphylococcus aureus isolates identified.

Antibiotic Notes:

(2) Organisms that are susceptible to Tetracycline are also considered susceptible to Doxycycline.

General Notes:

Antibiogram results, patient risk factors for resistant organisms, and resistance epidemiology should be considered together to help guide empiric treatment of initial infections. Treatment should be re-evaluated as additional information from culture and sensitivity become available.

Calculation of results based on first isolate per patient.

- 90-100% of isolates are susceptible to the antibiotic indicated (GOOD CHOICE)
- 21-89% of isolates are susceptible to the antibiotic indicated (INTERMEDIATE CHOICE)
- 0-20% of isolates are susceptible to the antibiotic indicated (POOR CHOICE)
- Value based on < 30 isolates. Statistical comparison on results with less than 30 isolates is unreliable. n = # of isolates tested.
- Antibiotic susceptibility testing is not typically performed on the organism.